Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
04:01pm, Monday, 22'nd Mar 2021
-- 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH -- -- 25% of EFX patients (3 of 12) showed NASH resolution --
Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients
06:30am, Monday, 22'nd Mar 2021
SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcohol
Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
08:00am, Tuesday, 16'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoh
Akero Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 04'th Jan 2021
SAN FRANCISCO--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (
Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience
12:00am, Thursday, 22'nd Oct 2020
Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience
Regulatory News: POXEL (Euronext – POXEL - FR0012432516, éligible PEA-PME), société biopharmaceutique spécialisée dans le développement de traitements
89bio: Near And Long-Term Investment Cases Excite As Company Targets NASH Opportunity (NASDAQ:ETNB)
11:01pm, Wednesday, 14'th Oct 2020
89bio has emerged as a competitive player in the race to have a treatment approved for nonalcoholic steatohepatitis (“NASH”) - a potential multi-billion dollar market.
Terns Pharmaceuticals to Present Positive Data on Single-Agent and Combination NASH Programs at The Liver Meeting® Digital Experience 2020
12:00am, Wednesday, 14'th Oct 2020
Terns Pharmaceuticals to Present Positive Data on Single-Agent and Combination NASH Programs at The Liver Meeting® Digital Experience 2020
Inventiva sa : Inventiva décroche une Breakthrough Therapy dans la NASH, une première depuis 2015
07:23am, Tuesday, 13'th Oct 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 12)
10X Genomics Inc (NASDAQ:...
Oct 07, 2020 (The Expresswire) --
Global “Nash Drugs Market” research report offers qualitative and quantitative insights in relation to industry growth...
The Daily Biotech Pulse: Mesoblast Slumps On FDA Rejection, AstraZeneca's Breakthrough Therapy Designation, 3 IPOs
12:00am, Friday, 02'nd Oct 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 1)
10X Genomics Inc (NASDAQ:...
GENFIT SA (GNFT) CEO Pascal Prigent on Q2 2020 Results - Earnings Call Transcript
01:49am, Thursday, 01'st Oct 2020
GENFIT SA (NASDAQ:GNFT) Q2 2020 Results Conference Call September 30, 2020 04:30 PM ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - CEO Dean Hum - Chief Scien
Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator
12:00am, Thursday, 01'st Oct 2020
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, in
